Actinium Pharmaceuticals, Inc.
ATNM- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001388320
No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Actinium Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 42 | 38 | −4 |
| Shares | 1.98M | 1.83M | −144.8K (−7.3%) |
| Value | $11.5M | $9.37M | −$2.12M (−18.5%) |
New holders (5)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 35,565 | $181.0K | 0.00% |
| Citadel Advisors LLC | 24,670 | $126.0K | 0.00% |
| Simplex Trading, LLC | 19,413 | $99.0K | 0.00% |
| Cutler Group LP | 1,000 | $5.00K | 0.00% |
| Glassman Wealth Services | 1 | $0 | 0.00% |
Sold out (9)
Institutions that held Actinium Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Sabby Management, LLC | 73,366 | $441.0K |
| Gsa Capital Partners LLP | 56,673 | $341.0K |
| Goodwin Daniel L | 10,000 | $60.0K |
| Bank Julius Baer & Co. Ltd, Zurich | 3,028 | $18.0K |
| Spire Wealth Management | 1,800 | $11.0K |
| Trust Co of Vermont | 50 | $0 |
| UBS Group AG | 50 | $0 |
| Endurant Capital Management LP | 66,666 | $0 |
| Truvestments Capital LLC | 60 | $0 |